8-bromo-3-methyl-2-phenylimidazo[1,2-a]pyridine | 1232038-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 8-bromo-3-methyl-2-phenylimidazo[1,2-a]pyridine
• CAS: 1232038-75-3
• 化学式: C₁₄H₁₁BrN₂
• 分子量: 287.159
• InChiKey: GJOACOCMFYQBOC-UHFFFAOYSA-N

物化性质

• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-(4-甲基-1H-咪唑-1-基)苯胺 、 8-bromo-3-methyl-2-phenylimidazo[1,2-a]pyridine 在 palladium diacetate R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 以71.5%的产率得到
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  [FR] DÉRIVÉS BICYCLIQUES SUBSTITUÉS D'IMIDAZOLE COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE

  摘要：

  本发明涉及新颖的Formula (I)中的取代双环咪唑衍生物，其中R0、R1、R3、R4、X、A1、A2、A3、A4、Y1、Y2和Y3的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包括将该新化合物作为活性成分的药物组合物以及将该化合物用作药物的用途。

  公开号：

  WO2010070008A1
• 作为产物：
  描述：

  2-氨基-3-溴吡啶 、 2-溴苯丙酮 在 氨 作用下， 以 乙醇 、 甲醇 、 二氯甲烷 为溶剂， 反应 48.0h， 以51.2%的产率得到8-bromo-3-methyl-2-phenylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  [FR] DÉRIVÉS BICYCLIQUES SUBSTITUÉS D'IMIDAZOLE COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE

  摘要：

  本发明涉及新颖的Formula (I)中的取代双环咪唑衍生物，其中R0、R1、R3、R4、X、A1、A2、A3、A4、Y1、Y2和Y3的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包括将该新化合物作为活性成分的药物组合物以及将该化合物用作药物的用途。

  公开号：

  WO2010070008A1

文献信息

• [EN] NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010089292A1

  公开（公告）日：2010-08-12

  The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的取代双环杂环化合物，其中Het1、Het2、A1、A2、A3和A4的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators
  作者：Francois Bischoff、Didier Berthelot、Michel De Cleyn、Gregor Macdonald、Garrett Minne、Daniel Oehlrich、Serge Pieters、Michel Surkyn、Andrés A. Trabanco、Gary Tresadern、Sven Van Brandt、Ingrid Velter、Mirko Zaja、Herman Borghys、Chantal Masungi、Marc Mercken、Harrie J. M. Gijsen

  DOI：10.1021/jm201710f

  日期：2012.11.8

  The design and the synthesis of several chemical subclasses of imidazole containing gamma-secretase modulators (GSMs) is described. Conformational restriction of pyridone 4 into bicyclic pyridone isosteres has led to compounds with high in vitro and in vivo potency. This has resulted, in the identification of benzimidazole 44a as a GSM with low nanomolar potency in vitro. In mouse, rat, and dog, this compound displayed the typical gamma-secretase modulatory profile by lowering A beta 42 and A beta 40 levels combined with an especially pronounced increase in A beta 38 and A beta 37 levels while leaving the total levels of amyloid peptides unchanged.
• NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS
  申请人：Janssen Pharmaceuticals, Inc.

  公开号：EP2393804B1

  公开（公告）日：2014-04-16
• SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  申请人：Gijsen Henricus Jacobus Maria

  公开号：US20110237580A1

  公开（公告）日：2011-09-29

  The present invention is concerned with novel substituted bicyclic imidazole derivatives of Formula (I) wherein R 0 , R 1 , R 3 , R 4 , X, A 1 , A 2 , A 3 , A 4 , Y 1 , Y 2 and Y 3 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel compound as an active ingredient as well as the use of said compounds as a medicament.
• BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160355517A1

  公开（公告）日：2016-12-08

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.